Evaluating Impurities in Drugs (Part II of III) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluating Impurities in Drugs (Part II of III)
In Part II of a three-part article, the authors examine impurities from chiral molecules, polymorphic contaminants, and genotoxic impurities.


Pharmaceutical Technology
Volume 36, Issue 3, pp. 58-72

30. F.J. Jamali, J. Pharm. Sci. 78 (9), 695–715 (1989).

31. "FDA's Policy Statement for the Development of New Stereoisomer Drugs," Chirality 4 (5), 338–340 (1992).

32. H. Wilson et al., J. Pharm. Biomed. Anal. 11 (11–12), 1167–1173 (1993).

33. A.G. Rauws, Chirality 6 (2), 72–75 (1994).

34. M. Gross et al., Drug Inf. J. 27 (2), 53–457 (1993).

35. W.L. Heydorn, Pharm. News 2, 19–21 (1995).

36. ICH, Q6A Document, Specification for New Drug Substances and Products: Chemical Substances, Step 2 version (1992).

37. J. Haleblian et al., J. Pharm. Sci. 58 (8) 911–929 (1969).

38. G.A. Stephenson et al., Adv. Drug. Deliv. Rev. 48, 67–90 (2001).

39. ICH, Q6A Specification: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances (1999).

40. G.G. Z. Zhang et al., Adv. Drug Deliv. Rev. 56 (3), 371–390 (2004).

41. S.R. Vippagunta et al., Adv. Drug Deliv. Rev. 48 (1), 3–26 (2001).

42. P.B. Molinoff, The Pharmacological Basis of Theraputics (McGraw Hill, New York, 1996), pp. 399–430.

43. S.M. Reutzel-Edens, Cryst. Growth Des. 3 (6) 897–907 (2003).

44. Eli Lilly, "Olanzapine Polymorph Crystal Form,"US Patent 5,736,541 (April 1998).

45. H.Y. Tong et al., Pharm. Res. 18 (6), 852–858 (2001).

46. H.H. Tong et al., Pharm.Res. 20 (9), 1423–1429 (2003).

47. D. Clemett et al., Drugs 59 (4), 815–827 (2000).

48. Teva Pharmaceutical Industries, "Isolated Bis-Linezolid, Preparation Thereof and Its Use as a Reference Standard, WO 2006/091848 A2, Aug. 2006.

49. Neuland Laboratories, "A Process for the Preparation of (5S)-(N)-[[3-[3-fluoro-4-4(4-morpholinly)phenyl-2-oxo-5-oxazolidinyl]methyl] acetamide," WO2010084514A2, July 2010.

50. Symed Labs, "Novel Process for the Preparation of Linezolid and Related Compounds," US Patent 2007/0032472, Feb, 2007.

51. B. A. Peralman, "Process to Produce Oxazolidiones," US Patent 2002/0095054, July 2002.

52. Pfizer, "Process for Preparing Linezolid," WO 2007/116284, Oct. 2007.

5 3. Pharmacia & Upjohn, "Process to Prepare Oxazolidinones," US Patent 5837870, Nov. 1998.

54. Jubilant Life Sciences, "Process for the Preparation of Linezolid," WO 2011/114241, Sept. 2011.

55. Pharmacia and Upjohn, "Substituted Oxazine and Thiazine Oxazolidinone Antimicrobials," US Patent 5688792, Nov. 1997.

56. D.C.M Chan et al., Curr. Med. Chem. 13 (4), 377–398 (2006).

57. Fortress Metro Hainan Tianyuan Pharmaceutical Technology Co., Ltd., "Nitro Compounds and the Preparation of Pemetrexed CN1827604A, Sept. 2006.

58. Wu Torrent, "Pemetrexed Intermediates and Preparation Methods, CN101085775A, Dec. 2007.

59. Dr. Reddy's Laboratories, "Process for Preparing Pemetrexed, WO 2011/019986 A2, Feb. 2011.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here